PDCD1 and cancer: Probiotics and/or bacteria consortia containing live bacteria such as Bifidobacteria, Lactobacillus, Propionibacterium and Streptococcus thermophiles combined with monoclonal antibodies (anti-PD-1 and anti-CTLA-4 antibodies) also significantly improve the outcomes of cancer patients with immunotherapy.